Collaboration brings together leading lung and breast imaging expertise to advance AI-driven cancer detection and early intervention.
Optellum, the leader in AI-enabled lung cancer diagnosis, announced it has entered a strategic agreement with Volpara Health, a Lunit company and a global leader in software for the early detection of cancer, designed to expand a patient’s picture of cancer risk. This agreement will enable Volpara customers, including over 3,500 facilities in the U.S. that rely on Volpara software for early detection, to gain access to Optellum’s Virtual Nodule Clinic software that identifies the probability that a lung nodule is cancerous.
With FDA clearance, comprehensive reimbursement, and a proven track record, Optellum helps providers identify more cancers at an earlier stage and make well-informed decisions on patient management and care pathways. The company’s Lung Cancer Prediction AI® complements Volpara’s tools that quantify breast tissue density, optimize mammography workflows, and refine risk assessments—ensuring clinicians can adopt a truly personalized approach to cancer diagnosis.
Also Read: DeepScribe Launches AI-Driven Automated E/M Coding System
“Every patient deserves the earliest possible diagnosis, and by coming together with Volpara, more clinicians will have a more complete picture of their patients’ health,” said Johnathan Watkins, CEO of Optellum. “In the field of cancer screening and diagnostics, AI-driven imaging and risk assessment tools will continue to impact the approach to early detection and treatment planning.”
“Getting more evidence-based, early detection technologies into the hands of clinicians will allow for more accurate detection and ultimately save more families from cancer,” said Teri Thomas, CEO of Volpara Health. “We are committed to being objective consultants to the institutions we serve and bringing them the best AI tools with the potential to translate into more life-saving advancements for their patients.”
With the capabilities to quantify patient risk for both breast and lung cancer, clinicians will have advanced evaluation metrics to prioritize patients and enable precision medicine.
Source: PRNewswire
